ID   NAMPT_HUMAN             Reviewed;         491 AA.
AC   P43490; A4D0Q9; A4D0R0; Q3KQV0; Q8WW95;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   22-JUL-2015, entry version 146.
DE   RecName: Full=Nicotinamide phosphoribosyltransferase;
DE            Short=NAmPRTase;
DE            Short=Nampt;
DE            EC=2.4.2.12;
DE   AltName: Full=Pre-B-cell colony-enhancing factor 1;
DE            Short=Pre-B cell-enhancing factor;
DE   AltName: Full=Visfatin;
GN   Name=NAMPT; Synonyms=PBEF, PBEF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=8289818;
RA   Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I.;
RT   "Cloning and characterization of the cDNA encoding a novel human pre-
RT   B-cell colony-enhancing factor.";
RL   Mol. Cell. Biol. 14:1431-1437(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-188, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   REVIEW.
RX   PubMed=22462624; DOI=10.1146/annurev-nutr-071811-150746;
RA   Dahl T.B., Holm S., Aukrust P., Halvorsen B.;
RT   "Visfatin/NAMPT: a multifaceted molecule with diverse roles in
RT   physiology and pathophysiology.";
RL   Annu. Rev. Nutr. 32:229-243(2012).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21741723; DOI=10.1016/j.diabres.2011.06.009;
RA   Bienertova-Vasku J., Bienert P., Zlamal F., Tomandl J., Tomandlova M.,
RA   Dostalova Z., Vasku A.;
RT   "Visfatin is secreted into the breast milk and is correlated with
RT   weight changes of the infant after the birth.";
RL   Diabetes Res. Clin. Pract. 96:355-361(2012).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24130902; DOI=10.1371/journal.pone.0078283;
RA   Romacho T., Villalobos L.A., Cercas E., Carraro R.,
RA   Sanchez-Ferrer C.F., Peiro C.;
RT   "Visfatin as a novel mediator released by inflamed human endothelial
RT   cells.";
RL   PLoS ONE 8:E78283-E78283(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE;
RP   PRODUCT AND INHIBITOR FK866, ENZYME REGULATION, MUTAGENESIS OF
RP   ASP-219; HIS-247 AND ARG-311, AND SUBUNIT.
RX   PubMed=16783377; DOI=10.1038/nsmb1105;
RA   Khan J.A., Tao X., Tong L.;
RT   "Molecular basis for the inhibition of human NMPRTase, a novel target
RT   for anticancer agents.";
RL   Nat. Struct. Mol. Biol. 13:582-588(2006).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-176.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Catalyzes the condensation of nicotinamide with 5-
CC       phosphoribosyl-1-pyrophosphate to yield nicotinamide
CC       mononucleotide, an intermediate in the biosynthesis of NAD. It is
CC       the rate limiting component in the mammalian NAD biosynthesis
CC       pathway. The secreted form behaves both as a cytokine with
CC       immunomodulating properties and an adipokine with anti-diabetic
CC       properties, it has no enzymatic activity, partly because of lack
CC       of activation by ATP, which has a low level in extracellular space
CC       and plasma. Plays a role in the modulation of circadian clock
CC       function. NAMPT-dependent oscillatory production of NAD regulates
CC       oscillation of clock target gene expression by releasing the core
CC       clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent
CC       SIRT1-mediated suppression (By similarity).
CC       {ECO:0000250|UniProtKB:Q99KQ4, ECO:0000269|PubMed:24130902}.
CC   -!- CATALYTIC ACTIVITY: Nicotinamide D-ribonucleotide + diphosphate =
CC       nicotinamide + 5-phospho-alpha-D-ribose 1-diphosphate.
CC   -!- ENZYME REGULATION: Inhibited by FK866. FK866 competes for the same
CC       binding site as nicotinamide, but due to its very low dissociation
CC       rate, it is essentially an irreversible inhibitor.
CC       {ECO:0000269|PubMed:16783377}.
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; nicotinamide
CC       D-ribonucleotide from 5-phospho-alpha-D-ribose 1-diphosphate and
CC       nicotinamide: step 1/1.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:16783377}.
CC   -!- INTERACTION:
CC       P02792:FTL; NbExp=3; IntAct=EBI-2829310, EBI-713279;
CC       Q01628:IFITM3; NbExp=3; IntAct=EBI-2829310, EBI-7932862;
CC       P03886:MT-ND1; NbExp=3; IntAct=EBI-2829310, EBI-1246156;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24130902}.
CC       Cytoplasm {ECO:0000250|UniProtKB:Q99KQ4}. Secreted
CC       {ECO:0000269|PubMed:21741723}. Note=Under non-inflammatory
CC       conditions, visfatin predominantly exhibits a granular pattern
CC       within the nucleus. Secreted by endothelial cells upon IL-1beta
CC       stimulation. Abundantly secreted in milk, reaching 100-fold higher
CC       concentrations compared to maternal serum.
CC       {ECO:0000269|PubMed:21741723, ECO:0000269|PubMed:24130902}.
CC   -!- TISSUE SPECIFICITY: Expressed in large amounts in bone marrow,
CC       liver tissue, and muscle. Also present in heart, placenta, lung,
CC       and kidney tissues.
CC   -!- SIMILARITY: Belongs to the NAPRTase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ96862.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAL24400.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NAMPTID43890ch7q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U02020; AAA17884.1; -; mRNA.
DR   EMBL; AK292851; BAF85540.1; -; mRNA.
DR   EMBL; AC007032; AAF19249.1; -; Genomic_DNA.
DR   EMBL; AC007032; AAQ96862.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH236947; EAL24399.1; -; Genomic_DNA.
DR   EMBL; CH236947; EAL24400.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471070; EAW83382.1; -; Genomic_DNA.
DR   EMBL; BC072439; AAH72439.1; -; mRNA.
DR   EMBL; BC106046; AAI06047.1; -; mRNA.
DR   CCDS; CCDS5737.1; -.
DR   PIR; A55927; A55927.
DR   RefSeq; NP_005737.1; NM_005746.2.
DR   RefSeq; XP_005250157.1; XM_005250100.1.
DR   UniGene; Hs.489615; -.
DR   PDB; 2E5B; X-ray; 2.00 A; A/B=1-491.
DR   PDB; 2E5C; X-ray; 2.20 A; A/B=1-491.
DR   PDB; 2E5D; X-ray; 2.00 A; A/B=1-491.
DR   PDB; 2GVG; X-ray; 2.20 A; A/B/C/D/E/F=1-491.
DR   PDB; 2GVJ; X-ray; 2.10 A; A/B=1-491.
DR   PDB; 3DGR; X-ray; 2.10 A; A/B=1-484.
DR   PDB; 3DHD; X-ray; 2.00 A; A/B=1-484.
DR   PDB; 3DHF; X-ray; 1.80 A; A/B=1-484.
DR   PDB; 3DKJ; X-ray; 2.00 A; A/B=1-484.
DR   PDB; 3DKL; X-ray; 1.89 A; A/B=1-484.
DR   PDB; 4JNM; X-ray; 2.20 A; A/B=1-491.
DR   PDB; 4JR5; X-ray; 1.91 A; A/B=1-491.
DR   PDB; 4KFN; X-ray; 1.60 A; A/B=1-491.
DR   PDB; 4KFO; X-ray; 1.60 A; A/B=1-491.
DR   PDB; 4KFP; X-ray; 1.84 A; A/B=1-491.
DR   PDB; 4L4L; X-ray; 2.12 A; A/B=1-491.
DR   PDB; 4L4M; X-ray; 2.44 A; A/B=1-491.
DR   PDB; 4LTS; X-ray; 1.69 A; A/B=1-491.
DR   PDB; 4LV9; X-ray; 1.81 A; A/B=1-491.
DR   PDB; 4LVA; X-ray; 1.55 A; A/B=1-491.
DR   PDB; 4LVB; X-ray; 1.84 A; A/B=1-491.
DR   PDB; 4LVD; X-ray; 1.75 A; A/B=1-491.
DR   PDB; 4LVF; X-ray; 1.50 A; A/B=1-491.
DR   PDB; 4LVG; X-ray; 1.70 A; A/B=1-491.
DR   PDB; 4LWW; X-ray; 1.64 A; A/B=1-491.
DR   PDB; 4M6P; X-ray; 1.75 A; A/B=1-491.
DR   PDB; 4M6Q; X-ray; 2.41 A; A/B=1-491.
DR   PDB; 4N9B; X-ray; 2.86 A; A/B=1-491.
DR   PDB; 4N9C; X-ray; 1.75 A; A/B=1-491.
DR   PDB; 4N9D; X-ray; 1.70 A; A/B=1-491.
DR   PDB; 4N9E; X-ray; 1.72 A; A/B=1-491.
DR   PDB; 4O0Z; X-ray; 2.05 A; A/B=1-491.
DR   PDB; 4O10; X-ray; 1.55 A; A/B=1-491.
DR   PDB; 4O12; X-ray; 2.50 A; A/B=1-491.
DR   PDB; 4O13; X-ray; 1.75 A; A/B=1-491.
DR   PDB; 4O14; X-ray; 1.87 A; A/B=1-491.
DR   PDB; 4O15; X-ray; 1.80 A; A/B=1-491.
DR   PDB; 4O16; X-ray; 1.78 A; A=1-491.
DR   PDB; 4O17; X-ray; 1.82 A; A/B=1-491.
DR   PDB; 4O18; X-ray; 1.92 A; A/B=1-491.
DR   PDB; 4O19; X-ray; 1.75 A; A/B=1-491.
DR   PDB; 4O1A; X-ray; 1.87 A; A/B=1-491.
DR   PDB; 4O1B; X-ray; 1.65 A; A/B=1-491.
DR   PDB; 4O1C; X-ray; 2.09 A; A/B=1-491.
DR   PDB; 4O1D; X-ray; 1.70 A; A/B=1-491.
DR   PDB; 4O28; X-ray; 2.00 A; A/B=1-491.
DR   PDB; 4WQ6; X-ray; 1.72 A; A/B=1-491.
DR   PDBsum; 2E5B; -.
DR   PDBsum; 2E5C; -.
DR   PDBsum; 2E5D; -.
DR   PDBsum; 2GVG; -.
DR   PDBsum; 2GVJ; -.
DR   PDBsum; 3DGR; -.
DR   PDBsum; 3DHD; -.
DR   PDBsum; 3DHF; -.
DR   PDBsum; 3DKJ; -.
DR   PDBsum; 3DKL; -.
DR   PDBsum; 4JNM; -.
DR   PDBsum; 4JR5; -.
DR   PDBsum; 4KFN; -.
DR   PDBsum; 4KFO; -.
DR   PDBsum; 4KFP; -.
DR   PDBsum; 4L4L; -.
DR   PDBsum; 4L4M; -.
DR   PDBsum; 4LTS; -.
DR   PDBsum; 4LV9; -.
DR   PDBsum; 4LVA; -.
DR   PDBsum; 4LVB; -.
DR   PDBsum; 4LVD; -.
DR   PDBsum; 4LVF; -.
DR   PDBsum; 4LVG; -.
DR   PDBsum; 4LWW; -.
DR   PDBsum; 4M6P; -.
DR   PDBsum; 4M6Q; -.
DR   PDBsum; 4N9B; -.
DR   PDBsum; 4N9C; -.
DR   PDBsum; 4N9D; -.
DR   PDBsum; 4N9E; -.
DR   PDBsum; 4O0Z; -.
DR   PDBsum; 4O10; -.
DR   PDBsum; 4O12; -.
DR   PDBsum; 4O13; -.
DR   PDBsum; 4O14; -.
DR   PDBsum; 4O15; -.
DR   PDBsum; 4O16; -.
DR   PDBsum; 4O17; -.
DR   PDBsum; 4O18; -.
DR   PDBsum; 4O19; -.
DR   PDBsum; 4O1A; -.
DR   PDBsum; 4O1B; -.
DR   PDBsum; 4O1C; -.
DR   PDBsum; 4O1D; -.
DR   PDBsum; 4O28; -.
DR   PDBsum; 4WQ6; -.
DR   ProteinModelPortal; P43490; -.
DR   SMR; P43490; 8-489.
DR   BioGrid; 115438; 19.
DR   DIP; DIP-29218N; -.
DR   IntAct; P43490; 10.
DR   MINT; MINT-4530953; -.
DR   STRING; 9606.ENSP00000222553; -.
DR   BindingDB; P43490; -.
DR   ChEMBL; CHEMBL1744525; -.
DR   PhosphoSite; P43490; -.
DR   BioMuta; NAMPT; -.
DR   DMDM; 1172027; -.
DR   MaxQB; P43490; -.
DR   PaxDb; P43490; -.
DR   PRIDE; P43490; -.
DR   DNASU; 10135; -.
DR   Ensembl; ENST00000222553; ENSP00000222553; ENSG00000105835.
DR   GeneID; 10135; -.
DR   KEGG; hsa:10135; -.
DR   UCSC; uc003vdq.3; human.
DR   CTD; 10135; -.
DR   GeneCards; GC07M105888; -.
DR   HGNC; HGNC:30092; NAMPT.
DR   HPA; CAB034349; -.
DR   HPA; HPA047776; -.
DR   HPA; HPA057722; -.
DR   MIM; 608764; gene.
DR   neXtProt; NX_P43490; -.
DR   PharmGKB; PA162396933; -.
DR   eggNOG; COG1488; -.
DR   GeneTree; ENSGT00390000006647; -.
DR   HOGENOM; HOG000216546; -.
DR   HOVERGEN; HBG000336; -.
DR   InParanoid; P43490; -.
DR   KO; K03462; -.
DR   OMA; KKFPITE; -.
DR   OrthoDB; EOG7PGDQH; -.
DR   PhylomeDB; P43490; -.
DR   TreeFam; TF333530; -.
DR   BRENDA; 2.4.2.12; 2681.
DR   Reactome; REACT_111118; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; REACT_11213; Nicotinamide salvaging.
DR   SABIO-RK; P43490; -.
DR   UniPathway; UPA00253; UER00890.
DR   ChiTaRS; NAMPT; human.
DR   EvolutionaryTrace; P43490; -.
DR   GeneWiki; Nicotinamide_phosphoribosyltransferase; -.
DR   GenomeRNAi; 10135; -.
DR   NextBio; 38341; -.
DR   PRO; PR:P43490; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; P43490; -.
DR   CleanEx; HS_NAMPT; -.
DR   ExpressionAtlas; P43490; baseline and differential.
DR   Genevisible; P43490; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005125; F:cytokine activity; TAS:ProtInc.
DR   GO; GO:0008144; F:drug binding; IEA:Ensembl.
DR   GO; GO:0047280; F:nicotinamide phosphoribosyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004514; F:nicotinate-nucleotide diphosphorylase (carboxylating) activity; IEA:InterPro.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; TAS:Reactome.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0009435; P:NAD biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0019674; P:NAD metabolic process; TAS:Reactome.
DR   GO; GO:0006769; P:nicotinamide metabolic process; TAS:Reactome.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006766; P:vitamin metabolic process; TAS:Reactome.
DR   GO; GO:0006767; P:water-soluble vitamin metabolic process; TAS:Reactome.
DR   InterPro; IPR007229; Nic_PRibTrfase-Fam.
DR   InterPro; IPR016471; Nicotinamide_PRibTrfase.
DR   InterPro; IPR002638; Quinolinate_PRibosylTrfase_C.
DR   PANTHER; PTHR11098; PTHR11098; 1.
DR   PANTHER; PTHR11098:SF2; PTHR11098:SF2; 1.
DR   Pfam; PF04095; NAPRTase; 1.
DR   PIRSF; PIRSF005943; NMPRT; 1.
DR   SUPFAM; SSF51690; SSF51690; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Biological rhythms; Complete proteome;
KW   Cytokine; Cytoplasm; Glycosyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Pyridine nucleotide biosynthesis; Reference proteome;
KW   Secreted; Transferase.
FT   CHAIN         1    491       Nicotinamide phosphoribosyltransferase.
FT                                /FTId=PRO_0000205863.
FT   REGION      311    313       Nicotinamide ribonucleotide binding.
FT   REGION      353    354       Nicotinamide ribonucleotide binding.
FT   BINDING     196    196       Diphosphate.
FT   BINDING     219    219       Nicotinamide ribonucleotide.
FT   BINDING     247    247       Diphosphate.
FT   BINDING     311    311       Diphosphate.
FT   BINDING     384    384       Nicotinamide ribonucleotide; via amide
FT                                nitrogen.
FT   BINDING     392    392       Nicotinamide ribonucleotide.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:22223895}.
FT   MOD_RES     188    188       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15592455}.
FT   VARIANT     176    176       L -> S (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036614.
FT   MUTAGEN     219    219       D->N,S: No effect on activity towards
FT                                nicotinamide. Alters specificity, so that
FT                                the enzyme acquires activity towards
FT                                nicotinic acid.
FT                                {ECO:0000269|PubMed:16783377}.
FT   MUTAGEN     247    247       H->A: Reduces activity towards
FT                                nicotinamide.
FT                                {ECO:0000269|PubMed:16783377}.
FT   MUTAGEN     311    311       R->D: Reduces activity towards
FT                                nicotinamide.
FT                                {ECO:0000269|PubMed:16783377}.
FT   HELIX        11     13       {ECO:0000244|PDB:4LVF}.
FT   STRAND       14     16       {ECO:0000244|PDB:4LVF}.
FT   HELIX        17     24       {ECO:0000244|PDB:4LVF}.
FT   STRAND       30     39       {ECO:0000244|PDB:4LVF}.
FT   STRAND       56     58       {ECO:0000244|PDB:4LVF}.
FT   HELIX        62     69       {ECO:0000244|PDB:4LVF}.
FT   HELIX        77     91       {ECO:0000244|PDB:4LVF}.
FT   HELIX        98    108       {ECO:0000244|PDB:4LVF}.
FT   STRAND      114    118       {ECO:0000244|PDB:4LVF}.
FT   STRAND      124    126       {ECO:0000244|PDB:4LVF}.
FT   STRAND      129    138       {ECO:0000244|PDB:4LVF}.
FT   HELIX       139    141       {ECO:0000244|PDB:4LVF}.
FT   HELIX       144    147       {ECO:0000244|PDB:4LVF}.
FT   HELIX       149    153       {ECO:0000244|PDB:4LVF}.
FT   HELIX       156    180       {ECO:0000244|PDB:4LVF}.
FT   HELIX       186    188       {ECO:0000244|PDB:4LVF}.
FT   STRAND      189    192       {ECO:0000244|PDB:4LVF}.
FT   HELIX       195    197       {ECO:0000244|PDB:4LVF}.
FT   HELIX       201    211       {ECO:0000244|PDB:4LVF}.
FT   TURN        212    214       {ECO:0000244|PDB:4LVF}.
FT   STRAND      216    220       {ECO:0000244|PDB:4LVF}.
FT   HELIX       222    230       {ECO:0000244|PDB:4LVF}.
FT   STRAND      234    236       {ECO:0000244|PDB:4LVF}.
FT   HELIX       247    251       {ECO:0000244|PDB:4LVF}.
FT   HELIX       255    257       {ECO:0000244|PDB:4LVF}.
FT   HELIX       258    268       {ECO:0000244|PDB:4LVF}.
FT   STRAND      270    272       {ECO:0000244|PDB:4LVF}.
FT   STRAND      274    277       {ECO:0000244|PDB:4LVF}.
FT   HELIX       283    288       {ECO:0000244|PDB:4LVF}.
FT   HELIX       289    294       {ECO:0000244|PDB:4LVF}.
FT   HELIX       296    299       {ECO:0000244|PDB:4LVF}.
FT   STRAND      308    311       {ECO:0000244|PDB:4LVF}.
FT   HELIX       317    331       {ECO:0000244|PDB:4LVF}.
FT   STRAND      338    340       {ECO:0000244|PDB:2GVJ}.
FT   STRAND      348    352       {ECO:0000244|PDB:4LVF}.
FT   HELIX       358    370       {ECO:0000244|PDB:4LVF}.
FT   HELIX       375    377       {ECO:0000244|PDB:4LVF}.
FT   STRAND      378    383       {ECO:0000244|PDB:4LVF}.
FT   HELIX       384    387       {ECO:0000244|PDB:4LVF}.
FT   TURN        392    396       {ECO:0000244|PDB:4LVF}.
FT   STRAND      397    406       {ECO:0000244|PDB:4LVF}.
FT   STRAND      409    412       {ECO:0000244|PDB:4LVF}.
FT   HELIX       421    423       {ECO:0000244|PDB:4LVF}.
FT   STRAND      431    434       {ECO:0000244|PDB:4LVF}.
FT   STRAND      440    443       {ECO:0000244|PDB:4LVF}.
FT   HELIX       447    450       {ECO:0000244|PDB:4LVF}.
FT   STRAND      453    455       {ECO:0000244|PDB:4M6P}.
FT   STRAND      459    463       {ECO:0000244|PDB:4LVF}.
FT   HELIX       473    479       {ECO:0000244|PDB:4LVF}.
FT   TURN        483    485       {ECO:0000244|PDB:4LVF}.
SQ   SEQUENCE   491 AA;  55521 MW;  6BF07B631B589AC0 CRC64;
     MNPAAEAEFN ILLATDSYKV THYKQYPPNT SKVYSYFECR EKKTENSKLR KVKYEETVFY
     GLQYILNKYL KGKVVTKEKI QEAKDVYKEH FQDDVFNEKG WNYILEKYDG HLPIEIKAVP
     EGFVIPRGNV LFTVENTDPE CYWLTNWIET ILVQSWYPIT VATNSREQKK ILAKYLLETS
     GNLDGLEYKL HDFGYRGVSS QETAGIGASA HLVNFKGTDT VAGLALIKKY YGTKDPVPGY
     SVPAAEHSTI TAWGKDHEKD AFEHIVTQFS SVPVSVVSDS YDIYNACEKI WGEDLRHLIV
     SRSTQAPLII RPDSGNPLDT VLKVLEILGK KFPVTENSKG YKLLPPYLRV IQGDGVDINT
     LQEIVEGMKQ KMWSIENIAF GSGGGLLQKL TRDLLNCSFK CSYVVTNGLG INVFKDPVAD
     PNKRSKKGRL SLHRTPAGNF VTLEEGKGDL EEYGQDLLHT VFKNGKVTKS YSFDEIRKNA
     QLNIELEAAH H
//
